The FDA has sent a warning letter to Haemonetics that alleges manufacturing problems at its Illinois facility, including the lack of quality-control procedures for its blood-collection devices. The agency gave the firm 15 days to respond. Company officials were not immediately available for comment.

Full Story:

Related Summaries